**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 52690

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Breast non-mass-like lesions on contrast-enhanced ultrasonography: Feature analysis, breast image reporting and data system classification assessment**

Xu P *et al.* Breast NMLs on contrast-enhanced US

Ping Xu, Min Yang, Yong Liu, Yan-Ping Li, Hong Zhang, Guang-Rui Shao

**Ping Xu,** Medical College of Shangdong University, Jinan 250100, Shandong Province, China

**Ping Xu, Min Yang, Yong Liu, Hong Zhang,** Department of Ultrasound, Beijing Shijitan Hospital affiliated to Capital Medical University, Beijing 100038, China

**Yan-Ping Li,** Department of Breast Surgery, Beijing Shijitan Hospital affiliated to Capital Medical University, Beijing 100038, China

**Guang-Rui Shao,** Department of Radiology, Second Hospital of Shandong University, Jinan 250100, Shandong Province, China

**Author contributions:** All authors helped to perform the research; Xu P and Yang M contributed equally to this paper; Xu P and Min Yang M contributed to manuscript writing, performing ultrasound examinations, and data analysis; Shao GR contributed to manuscript writing of the manuscript, and conception and design of the study; Liu Y and Li YP contributed to writing of the manuscript, and conception and design of the study; Zhang H contributed to performing the ultrasound examinations.

**Corresponding author:** **Guang-Rui Shao, PhD, Chief Doctor, Department Director,** Department of Radiology, Second Hospital of Shandong University, No. 247 Beiyuan Street, Jinan 250100, Shandong Province, China. grshao6088@163.com

**Received:** November 25, 2019

**Revised:** December 27, 2019

**Accepted:** January 8, 2020

**Published online:**

**Abstract**

BACKGROUND

Breast non-mass-like lesions (NMLs) account for 9.2% of all breast lesions. The specificity of the ultrasound diagnosis of NMLs is low, and it cannot be objectively classified according to the 5th Edition of the Breast Imaging Reporting and Data System (BI-RADS). Contrast-enhanced ultrasound (CEUS) can help to differentiate and classify breast lesions but there are few studies on NMLs alone.

AIM

To analyze the features of benign and malignant breast NMLs in grayscale ultrasonography (US), color Doppler flow imaging (CDFI) and CEUS, and to explore the efficacy of the combined diagnosis of NMLs and the effect of CEUS on the BI-RADS classification of NMLs.

METHODS

A total of 51 breast NMLs verified by pathology were analyzed in our hospital from January 2017 to April 2019. All lesions were examined by US, CDFI and CEUS, and their features from those examinations were analyzed. With pathology as the gold standard, binary logic regression was used to analyze the independent risk factors for malignant breast NMLs, and a regression equation was established to calculate the efficiency of combined diagnosis. Based on the regression equation, the combined diagnostic efficiency of US combined with CEUS (US + CEUS) was determined. The initial BI-RADS-US classification of NMLs was adjusted according to the independent risk factors identified by CEUS, and the diagnostic efficiency of CEUS combined with BI-RADS (CEUS + BI-RADS) was calculated based on the results. ROC curves were drawn to compare the diagnostic values of the three methods, including US, US + CEUS, and CEUS + BI-RADS, for benign and malignant NMLs.

RESULTS

Microcalcification, enhancement time, enhancement intensity, lesion scope, and peripheral blood vessels were significantly different between benign and malignant NMLs. Among these features, microcalcification, higher enhancement, and lesion scope were identified as independent risk factors for malignant breast NMLs. When US, US + CEUS, and CEUS + BI-RADS were used to identify the benign and malignant breast NMLs, their sensitivity rates were 82.6%, 91.3%, and 87.0%, respectively; their specificity rates were 71.4%, 89.2%, and 92.9%, respectively; their positive predictive values were 70.4%, 87.5%, and 90.9%, respectively; their negative predictive values were 83.3%, 92.6%, and 89.7%, respectively; their accuracy rates were 76.5%, 90.2%, and 90.2%, respectively; and their corresponding areas under ROC curves were 0.752, 0.877 and 0.903, respectively. *Z* tests showed that the area under the ROC curve of US was statistically smaller than that of US + CEUS and CEUS + BI-RADS, and there was no statistical difference between US + CEUS and CEUS + BI-RADS.

CONCLUSION

US combined with CEUS can improve diagnostic efficiency for NMLs. The adjustment of the BI-RADS classification according to the features of contrast-enhanced US of NMLs enables the diagnostic results to be simple and intuitive, facilitates the management of NMLs, and effectively reduces the incidence of unnecessary biopsy.

**Key words:** Breast tumor; Ultrasonography; Contrast agents; Feature exploration; Diagnosis; Non-mass-like lesions

Xu P, Yang M, Liu Y, Li YP, Zhang H, Shao GR. Breast non-mass-like lesions on contrast-enhanced ultrasonography: feature analysis, breast image reporting and data system classification assessment. *World J Clin Cases* 2020; In press

**Core tip:** Conventional ultrasound diagnosis of non-mass-like lesions in the breast has low specificity, and non-mass-like lesions cannot be classified according to the fifth edition of Breast Imaging Reporting and Data System published by the American College of Radiology. This study aimed to improve the diagnostic efficacy by contrast-enhanced ultrasound and conventional ultrasound, and to explore the effect of contrast-enhanced ultrasound on the classification of non-mass-like lesions in the Breast Imaging Reporting and Data System.

**INTRODUCTION**

Breast non-mass-like lesions (NMLs)[1] refer to lesions that do not have clear boundaries on ultrasonography (US), and that do not have spatial mass effects in two or more different scanning directions, accounting for 9.2% of all breast lesions[2]. The specificity of the ultrasound diagnosis of NMLs is low[3,4]. NMLs cannot be objectively classified according to the fifth edition of the Breast Imaging Reporting and Data System (BI-RADS) standard issued by the American College of Radiology (ACR). Contrast-enhanced ultrasound (CEUS) can indicate the distribution and morphological information of the blood vessels in these lesions, but there are few studies on the CEUS features of NMLs, and the effect of the CEUS features of NMLs on BI-RADS classification is still unclear. Therefore, this study aims to: (1) explore the features of US, color Doppler flow imaging (CDFI) and CEUS of NMLs; (2) explore the efficacy of the combined diagnosis by US and CEUS; and (3) investigate the effect of CEUS features on the initial BI-RADS classification of NMLs, and the effect of the combined application of CEUS and the BI-RADS classification system on the diagnosis and clinical strategy of NMLs by including CEUS in the BI-RADS classification system.

**MATERIALS AND METHODS**

***Patients***

A retrospective study was performed on 51 patients (all of whom were women and 29-years-old to 64-years-old, with an average age of 45.35 ± 10.42 years) with breast NMLs who underwent breast CEUS from January 2017 to April 2019. The maximum diameter of the masses was 0.8-3.5 cm, the masses were palpable in 15 cases, and 12 cases had the symptom of nipple discharge. The pathological results of all focuses were obtained by puncture or surgery.

Inclusion criteria were US features meeting the criteria for NMLs. Exclusion criteria were biopsy or surgery performed in the lesion area, pathology not available, or CEUS results being incomplete. This study was approved by the Ethics Committee of our hospital. All subjects were informed of the purpose and risks of the examination, and signed informed consent was obtained prior to undergoing contrast-enhanced US and ultrasound-guided breast biopsy.

***Ultrasonic examination method***

US, CDFI, and CEUS were performed for each lesion. All examinations were performed by three sonographers with more than 10 years of experience in breast US. US, CDFI and CEUS were performed with a GE LOGIQ E9 equipped with 15 L (US examination) and 9 L (CEUS examination) linear transducers. The contrast agent used was SonoVue (Bracco Imaging B.V., Geneva, Switzerland), and the consumption was 4.8 mL for each lesion.

***Analysis of US***

**Analysis of conventional US**: Location, maximum diameter, echo pattern, architectural distortion, ductal changes, microcalcifications (strong echo < 2 mm in diameter[5]), posterior features, and the tumefaction in axillary lymph nodes were observed and recorded. All lesions were initially classified according to the BI-RADS-US classification of breast NMLs published by Ko *et al*[1]: type I for ductal NML pattern (Ib with calcification, Ia without); type II for non-ductal NML pattern (IIb with calcification, IIa without); type III NMLs with architectural distortion; and type IV NMLs with posterior acoustic shadowing. Type IIa was correlated with BI-RADS categories 4a; types Ia, III and IV were correlated with 4b; and types Ib and IIb were correlated with 4c. The cutoff points of the benign and malignant groups were 4a and 4b. Type 4a was benign; types 4b and 4c were malignant. Biopsy is recommended for 4a and above.

**Analysis of CDFI:** Referring to Adler’s grade, grades 0-1 were determined to reflect scarce blood supply, and grades II- III were determined to reflect an abundant blood supply.

**Analysis of CEUS:** Enhancement time (earlier, synchronous, later), enhancement intensity (hypo-, iso- or hyper-enhanced), enhancement mode (homogeneous or heterogeneous), enhancement direction (centripetal, centrifugal or diffuse), lesion scope (expansion, without expansion), peripheral blood vessels: radial perfusion or penetration perfusion (with or without), and regression time (earlier, later, synchronous) were recorded. The enhancement time, regression time and enhancement degree of focus were all based on the surrounding normal breast tissues.

***Pathological grouping***

Pathology was divided into two groups, namely group A (benign lesion group) and group B (malignant lesion group). Group A was divided into group A2 (precancerous lesion group) and group A1 (another benign lesion group). Precancerous lesions include sclerosing adenosis, atypical ductal or lobular hyperplasia, ductal epithelial florid hyperplasia (high ductal epithelial hyperplasia) [6], and epithelial columnar cell lesions[7].

***Statistical analysis***

All data were entered into the database in Excel, and statistical analysis was performed with SPSS 21.0 statistical software. The experimental data were all enumeration data expressed by frequency or percentage, and the chi-square test was used to analyze the differences in the features of US, CDFI and CEUS in the benign and malignant groups. Binary logistic regression was used to determine the independent risk factors for malignant NMLs. With independent risk factors as independent variables, and pathological results as dependent variables, a logistic regression equation was built to calculate diagnostic efficiency. Based on the regression equation, the combined diagnostic efficiency of US + CEUS was obtained. The initial BI-RADS classification for NMLs was adjusted according to independent risk factors from CEUS to obtain the CEUS + BI-RADS diagnostic efficacy. Finally, ROC curves were drawn to compare the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy and area under the curve of the three methods. *P* < 0.05 suggested that the difference is statistically significant.

**RESULTS**

Of the 51 cases included in this study, 28 focuses (54.90%) were benign, of which 3 (5.89%) were combined with precancerous lesions; additionally, 23 focuses (45.10%) were malignant. The pathology of the lesions is shown in Table 1.

***Clinical information and ultrasound imaging between benign and malignant NMLs***

Comparisons of clinical information and US, CDFI and CEUS imaging between benign and malignant NMLs are shown in Tables 2 and 3.

The Table shows no significant difference in age and clinical symptoms in the two groups; that is, these factors have no effect on pathology.

In the US features of NMLs, microcalcifications were different between benign and malignant NMLs (*P* = 0.001), indicating that microcalcifications were associated with malignant NMLs.

Regarding CEUS features, enhancement time (*P* = 0.006), enhancement intensity (*P* = 0.002), lesion scope (*P* = 0.000), and peripheral blood vessels (*P* = 0.046) were different between benign and malignant NMLs. Earlier enhancement, higher enhancement, range expansion, and lesions of peripheral blood vessels in contrast-enhanced US suggested malignant lesions.

***Independent risk factors and logistic regression formula***

Binary logistic regression analysis was used to identify the independent risk factors for malignant NMLs. The selected risk factors included microcalcifications, enhancement time, enhancement intensity, lesion scope, and peripheral blood vessels. Binary logistic regression analysis was conducted for all of these factors, and microcalcifications (*P* = 0.035), higher enhancement (*P* = 0.041), and lesion scope (*P* = 0.008) were identified as independent risk factors. The regression equation is as follows:

Logit (*P*) = -27.266 + (4.008 × combined microcalcification) + (5.386 × peripheral blood vessels) + (4.885 × higher enhancement)

The area under the ROC curve obtained by this equation was 0.907. When the cut-off value was 0.5, the sensitivity was 95.7% and the specificity was 85.7%.

***Combined diagnosis based on the regression equation***

Among the three risk factors (microcalcifications, higher enhancement, and lesion scope), lesions with no or only one risk factor were defined as possibly benign, and lesions with two or three risk factors were defined as potentially malignant. The sensitivity, specificity, PPV, NPV and accuracy of the diagnosis by this method were 87.0%, 92.9%, 90.9%, 89.7% and 90.2%, respectively.

***Adjustment of the initial BI-RADS classification of 51 NMLs according to CEUS features***

The independent risk factors identified by CEUS for malignant NMLs were higher enhancement and lesion scope. The adjustment method is shown in Table 4. According to the number of contrast-enhanced US features that were independent risk factors for NMLs, the classifications included decreased (Figure 1), remained unchanged (Figure 2) or increased (Figure 3).

The BI-RADS classifications for 51 cases of NMLs before and after adjustment are shown in Table 5.

As shown in Table 5, after adjustment, classification of the 51 cases changed, showing a decrease in the number of type 4 cases (4a decreased by 12 cases, 4b decreased by 4 cases, and 4c decreased by 5 cases) and an increase in the number of type 3 and type 5 cases (type 2 increased by 12 cases and type 5 increased by 9 cases). After adjusting the classification of NMLs according to the independent risk factors identified by contrast-enhanced US, the sensitivity, specificity, PPV, NPV and accuracy of NML diagnosis were 91.3%, 89.2%, 87.5%, 92.6% and 90.2%, respectively.

***ROC curves***

The ROC curves of the US, US + CEUS, and CEUS + BI-RADS methods are shown in Figure 4, and their diagnostic efficiency is shown in Table 6. Areas under the curves for the US, US + CEUS, CEUS + BI-RADS were 0.752, 0.877, and 0.903, respectively. The Table shows that the diagnostic sensitivity and specificity of US + CEUS and CEUS + BI-RADS methods were significantly improved compared with that of US, and the area under the curve between US and US + CEUS (*Z* = 2.050, *P* = 0.040) and between US and CEUS + BI-RADS (*Z* = 3.280, *P* = 0.001) were significantly different. There was no significant difference in the areas under the curves between US + CEUS and CEUS + BI-RADS (*Z* = 0.545, *P* = 0.586).

**DISCUSSION**

Breast NMLs are very common in the clinic, accounting for 9.2% of all breast lesions[4]. The pathology of benign NMLs is mostly adenosis, and malignant NMLs are mostly intraductal carcinomas and invasive ductal carcinomas. ACR BI-RADS-US cannot classify breast NMLs, and has low diagnostic specificity[1,3]. Contrast-enhanced US can provide information on the blood supply of the lesions, but there are few studies on the contrast-enhanced US features of NMLs. Our study aimed to investigate the features of US, CDFI and CEUS in benign and malignant NMLs, and to explore the efficacy of a combined diagnosis. Additionally, the initial BI-RADS classification and CEUS were combined to facilitate the management of NMLs and clinical communication, providing a basis for clinical treatment.

Compared with breast mass-like lesions, the grayscale US of NMLs is usually hypoechoic without clear boundaries, and the pattern is usually irregular and mainly characterized by a striped or flaky hypoecho (27/51, 52.94%), duct ectasia (22/51, 43.14%), microcalcification (17/51, 33.33%), structural distortion (27/51, 19.61%), rear echo attenuation (7/51, 13.73%), *etc*. Of the above US features, only microcalcifications were different in benign and malignant NMLs, and microcalcifications were identified as an independent risk factor for malignant NMLs, suggesting that microcalcification was associated with malignant NMLs. This finding is consistent with previous studies[3,8]. The PPV of combined microcalcification in the hypoecho zone can reach 78.26%[3]. For this reason, when Ko *et al*[1] conducted BI-RADS-US classification for NMLs, they viewed microcalcification as an important risk sign.

CEUS can objectively and noninvasively evaluate the blood supply of NMLs, thus helping identify benign and malignant NMLs[9,10]. Many studies have reported the contrast-enhanced US features of breast cancer[11-13]. In a study by Wang *et al*[12], the independent risk factors for breast cancer were enhancement intensity, enhancement sequence, enhancement boundary, peripheral blood vessels and increased diameter. Xiao *et al*[13] viewed lesion scope, boundary and shape as independent risk factors for breast cancer. Since the number of breast NMLs is lower in breast lesions, previous studies[12,13] tended to explore the features, boundaries and forms of mass-like lesions, which had important diagnostic significance.

Our study found that higher enhancement and lesion scope were independent risk factors for malignant NMLs. The finding of higher enhancement as an independent risk factor for malignant NMLs is consistent with the studies of Zhang *et al*[11]and Wang *et al*[12]. Previous studies[14] have shown that breast focuses were associated with increased expression of vascular endothelial growth factor and increased tumor microvessel density in the development of atypical hyperplasia, carcinoma *in situ*, and invasive carcinoma. Microvessel density is considered to be an independent prognostic factor for breast cancer, and is associated with histological grade and proliferative activity to some extent[15,16]. The enhancement intensity reflects the abundance of the blood supply of the focus, and has a good correlation with the microvessel density of the focus[17], suggesting that enhancement intensity can reflect the proliferative activity of the focus and may be related to the prognosis of NMLs. In this study, 16 cases (16/23, 69.57%) in the malignant group and only 6 cases (6/28, 21.43%) in the benign group showed higher enhancement, of which 2 cases had precancerous lesions, suggesting that the higher enhancement in NMLs suggests the active proliferation of the focus, and that microvascular changes may precede pathological changes during the progression from benign lesions to malignant lesions.

In addition to enhancement intensity, lesion range was also identified as an independent risk factor for malignant NMLs, similar to the findings of previous studies[12,13]. van Esser *et al*[18] found that grayscale US often underestimated the size of breast cancer foci, especially those of intraductal carcinoma[19], while the maximum value measured by contrast-enhanced US was closer to the measured value of surgical specimen pathology. This suggested that the size and shape of the lesion identified by contrast-enhanced US were closer to the true state of the lesion. Since most NMLs are mixed with normal glands, only lesions with low echo on grayscale US are identified. In the contrast-enhanced state, the baseline echo of the gland is masked, only the blood supply information is displayed, and the overall shape of the malignant NMLs is shown, showing a wide range after contrast-enhanced US (15/23, 65.23%). Some studies have shown that there were more neoplastic microvessels around the malignant breast lesions than in the center[20], and contrast-enhanced US showed higher peripheral enhancement intensity[21]. This study did not observe this finding, which may be due to the small number of cases in our study, the large proportion of intraductal cancers in the malignant cases, and their weak invasiveness.

In addition to higher enhancement and lesion range, peripheral blood vessels and enhancement time were significantly different between benign and malignant NMLs. The lesions with earlier enhancement (20/51, 39.23%) and peripheral lesions around the lesion (19/51, 37.25%) tended to be malignant. Earlier enhancement and the appearance of peripheral blood vessels reflected the formation of abnormal blood vessels. Although these factors were not identified as independent risk factors, they provided some help for diagnosis.

In our study, there were several indicators that differed from previous studies: age, accessibility of the mass, and lesion blood supply identified by color Doppler US[22]. These differences may be related to several factors, such as fewer enrolled cases, differences among operators, and instrument performance and settings. Nonetheless, these three indicators can also provide a reference for diagnosis.

Considering the microcalcification and blood supply information of NMLs, combining the risk factors identified by grayscale US and contrast-enhanced US, lesions with one risk factor were classified as “possibly benign”, and lesions with two or three risk factors were classified as “possibly malignant”. The diagnostic efficiency of this method improved compared with that of grayscale US, in which the sensitivity, specificity, PPV, NPV and accuracy were 87.0%, 92.9%, 90.9%, 89.7% and 90.2%, respectively. The method is simple and easy, but its result cannot grade the risks of breast NMLs, which is not conducive to the management of NMLs.

In clinical work, the BI-RADS-US classification issued by ACR is very effective in the diagnosis and management of breast nodules. Unfortunately, the fifth edition of the ACR BI-RADS-US standard does not objectively classify NMLs. There is no unified method for the classification of NMLs. Different scholars have also explained it differently, but their diagnostic performance was similar[1,3,5,8]. A study showed that[23] the malignancy rate of NMLs may be greater than 2%, so NMLs should at least be classified as type 4a lesions. Therefore, the initial classification of NMLs in this study used the classification method of BI-RADS-US for NMLs developed by Ko *et al*[1], and the lesions were classified into types 4a, 4b, and 4c according to grayscale US features. Contrast-enhanced US provides blood supply information for breast lesions, so the diagnostic efficiency can be effectively improved if its results are included in the BI-RADS-US classification system[11-13]. Different studies have used different methods, which can be divided into counting methods[11], integral methods[13] and pattern methods[12]. Since the BI-RADS-US classification predicts the malignant probability of NMLs based on the number of two-dimensional ultrasound risk signs, this study used the counting method, that is, the method in which the initial classification is adjusted according to the number of independent risk factors identified by contrast-enhanced US features. The adjustment method is shown in Table 4. After adjusting the classification, the diagnostic efficiency was significantly higher than that of US (*P* = 0.001), which was similar to the diagnostic efficiency of US + CEUS (*P* = 0.586). However, the adjustment of BI-RADS classification was more convenient to combine with the grayscale US results, and facilitated the management of NML lesions and clinician communication.

In this study, before and after the classification adjustment of 51 cases of NMLs, the distribution of cases changed. Before adjusting the classification, all NMLs were type 4. After adjusting the classification, the numbers of type 3 and 5 lesions increased (type 3 increased by 19, type 5 by 12), and only 20 cases were type 4 focuses. According to the recommendation of BI-RADS-US classification, type 3 lesions can be subject to follow-up observation. After adjusting the classification, 19 patients could be converted from the recommended biopsy to follow-up observation, which effectively reduced unnecessary biopsy. The decrease in type 4 lesions and the increase in type 3 and 5 lesions enable clinicians to have a more objective understanding of the risk classification of focuses, and can more effectively guide clinical decision-making[24].

It is worth noting that of the three benign NMLs misdiagnosed by the adjusted BI-RADS classification, the lesion pathology of two cases showed precancerous lesions, namely sclerosing adenosis and atypical ductal epithelial dysplasia. Some of the precancerous lesions of the breast can develop into cancer; the highest cancer rate in 25 years was 46.0%[25], and its imaging diagnosis revealed certain difficulties[26]. Contrast-enhanced US can detect neovascularization of the lesion early, suggesting the potential diagnostic value for precancerous lesions. Another misdiagnosed case was plasma cell mastitis. Inflammatory lesions are rich in blood supply, and easily spread to surrounding perilobular and interlobular tissues[27]. It is difficult to identify malignant breast lesions using contrast-enhanced US. However, inflammatory lesions have clinical symptoms, and should be comprehensively diagnosed.

In this study, two cases of breast cancer were missed, and one case was mucinous carcinoma. Mucinous carcinoma forms a mucus lake due to abundant mucin, which is characterized by heterogeneity of enhancement or peripheral enhancement only[28]. Moreover, because it was invasive carcinoma, there were no obvious changes in the enhanced range, and peripheral blood vessels were lacking, leading to a missed diagnosis of the lesions. Another case was intraductal carcinoma with a maximum diameter of approximately 1 cm. The focus was small, and the body’s immune mechanism formed an immune response zone around the focus, inhibiting the formation of peripheral microvessels. The lack of deformed blood vessels led to misdiagnosis.

The limitations of this study were that the sample size was small, and the sample size of precancerous lesions was only 3 cases, so large samples from multiple centers should be studied in the future.

In conclusion, compared with mass-like breast lesions, NMLs have unique contrast-enhanced features. Malignant NMLs usually show earlier enhancement, higher enhancement, increased range, and the appearance of peripheral blood vessels. Among NMLs, higher enhancement and lesion range are independent risk factors for malignant NMLs. Grayscale US combined with contrast-enhanced US can improve diagnostic efficiency. Adjustment of the initial BI-RADS classification according to independent risk factors identified by contrast-enhanced US significantly improved the diagnostic efficiency compared with that of type B US. The diagnostic results of this method are objective and direct. This method is convenient for the management of NMLs and clinician communication, effectively reduces unnecessary biopsy, and provides the basis for providing patients with more personalized clinical strategies.

**Article Highlights**

***Research background***

The diagnosis of breast non-mass-like lesions (NMLs) by ultrasonography (US) is not satisfactory. Contrast-enhanced ultrasound (CEUS) can provide additional information for the differentiation of breast lesions. However, there are few studies about the characteristics and application of CEUS in breast NMLs.

***Research motivation***

Improve the diagnostic efficiency of breast NMLs by combining conventional ultrasound with CEUS.

***Research objectives***

To explore the CEUS features of breast NMLs, and to improve the diagnostic efficiency combined with the Breast Imaging Reporting and Data System (BI-RADS).

***Research methods***

A retrospective study was carried out in 51 breast NMLs. The independent risk factors of malignant NMLs were identified by binary logistics regression, with pathology as the gold standard, and the independent risk factors of CEUS were used to modify the initial BI-RADS classification of NMLs.

***Research results***

Malignant breast NMLs show high enhancement and enlarged range on CEUS. The diagnostic efficiency can be improved by conventional ultrasound combined with CEUS.

***Research conclusions***

US combined with CEUS can improve diagnostic efficiency for NMLs. CEUS combined with the BI-RADS system enables the diagnostic results to be simple and intuitive, and effectively reduces the incidence of unnecessary biopsy.

***Research perspectives***

Combined diagnosis of breast NMLs, and fusion with the existing BI-RADS classification system.

**REFERENCES**

1 **Ko KH**, Hsu HH, Yu JC, Peng YJ, Tung HJ, Chu CM, Chang TH, Chang WC, Wu YC, Lin YP, Hsu GC. Non-mass-like breast lesions at ultrasonography: feature analysis and BI-RADS assessment. *Eur J Radiol* 2015; **84**: 77-85 [PMID: 25455412 DOI: 10.1016/j.ejrad.2014.10.010]

2 **Stöblen F**, Landt S, Ishaq R, Stelkens-Gebhardt R, Rezai M, Skaane P, Blohmer JU, Sehouli J, Kümmel S. High-frequency breast ultrasound for the detection of microcalcifications and associated masses in BI-RADS 4a patients. *Anticancer Res* 2011; **31**: 2575-2581 [PMID: 21778307]

3 **Wang ZL**, Li N, Li M, Wan WB. Non-mass-like lesions on breast ultrasound: classification and correlation with histology. *Radiol Med* 2015; **120**: 905-910 [PMID: 25725790 DOI: 10.1007/s11547-014-0493-x]

4 **Ikeda T**, Bando H, Iguchi A, Tanaka Y, Tohno E, Hara H. Malignant lymphoma of the breast in a male patient: ultrasound imaging features. *Breast Cancer* 2015; **22**: 201-205 [PMID: 22396322 DOI: 10.1007/s12282-012-0349-y]

5 **Li L**, Zhou X, Zhao X, Hao S, Yao J, Zhong W, Zhi H. B-Mode Ultrasound Combined with Color Doppler and Strain Elastography in the Diagnosis of Non-mass Breast Lesions: A Prospective Study. *Ultrasound Med Biol* 2017; **43**: 2582-2590 [PMID: 28844465 DOI: 10.1016/j.ultrasmedbio.2017.07.014]

6 **Danforth DN Jr**. Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer. *Breast Cancer (Auckl)* 2016; **10**: 109-146 [PMID: 27559297 DOI: 10.4137/BCBCR.S39384]

7 **Gomes DS**, Porto SS, Balabram D, Gobbi H. Inter-observer variability between general pathologists and a specialist in breast pathology in the diagnosis of lobular neoplasia, columnar cell lesions, atypical ductal hyperplasia and ductal carcinoma in situ of the breast. *Diagn Pathol* 2014; **9**: 121 [PMID: 24948027 DOI: 10.1186/1746-1596-9-121]

8 **Park JW**, Ko KH, Kim EK, Kuzmiak CM, Jung HK. Non-mass breast lesions on ultrasound: final outcomes and predictors of malignancy. *Acta Radiol* 2017; **58**: 1054-1060 [PMID: 28114809 DOI: 10.1177/0284185116683574]

9 **Balleyguier C**, Opolon P, Mathieu MC, Athanasiou A, Garbay JR, Delaloge S, Dromain C. New potential and applications of contrast-enhanced ultrasound of the breast: Own investigations and review of the literature. *Eur J Radiol* 2009; **69**: 14-23 [PMID: 18977102 DOI: 10.1016/j.ejrad.2008.07.037]

10 **Zhao H**, Xu R, Ouyang Q, Chen L, Dong B, Huihua Y. Contrast-enhanced ultrasound is helpful in the differentiation of malignant and benign breast lesions. *Eur J Radiol* 2010; **73**: 288-293 [PMID: 19559551 DOI: 10.1016/j.ejrad.2009.05.043]

11 **Zhang W**, Xiao X, Xu X, Liang M, Wu H, Ruan J, Luo B. Non-Mass Breast Lesions on Ultrasound: Feature Exploration and Multimode Ultrasonic Diagnosis. *Ultrasound Med Biol* 2018; **44**: 1703-1711 [PMID: 29861297 DOI: 10.1016/j.ultrasmedbio.2018.05.005]

12 **Wang Y**, Fan W, Zhao S, Zhang K, Zhang L, Zhang P, Ma R. Qualitative, quantitative and combination score systems in differential diagnosis of breast lesions by contrast-enhanced ultrasound. *Eur J Radiol* 2016; **85**: 48-54 [PMID: 26724648 DOI: 10.1016/j.ejrad.2015.10.017]

13 **Xiao X**, Ou B, Yang H, Wu H, Luo B. Breast contrast-enhanced ultrasound: is a scoring system feasible? A preliminary study in China. *PLoS One* 2014; **9**: e105517 [PMID: 25133534 DOI: 10.1371/journal.pone.0105517]

14 **Cho T**, Shiozawa E, Urushibara F, Arai N, Funaki T, Takehara Y, Tazawa S, Misawa M, Homma M, Norose T, Omatsu M, Miyachi H, Yamochi T, Kunimura T, Tate G, Ishida F, Kudo SE, Takimoto M. The role of microvessel density, lymph node metastasis, and tumor size as prognostic factors of distant metastasis in colorectal cancer. *Oncol Lett* 2017; **13**: 4327-4333 [PMID: 28599434 DOI: 10.3892/ol.2017.5959]

15 **Teifke A**, Behr O, Schmidt M, Victor A, Vomweg TW, Thelen M, Lehr HA. Dynamic MR imaging of breast lesions: correlation with microvessel distribution pattern and histologic characteristics of prognosis. *Radiology* 2006; **239**: 351-360 [PMID: 16569783 DOI: 10.1148/radiol.2392050205]

16 **Fridman V**, Humblet C, Bonjean K, Boniver J. Assessment of tumor angiogenesis in invasive breast carcinomas: absence of correlation with prognosis and pathological factors. *Virchows Arch* 2000; **437**: 611-617 [PMID: 11193472 DOI: 10.1007/s004280000292]

17 **Yuan Z**, Quan J, Yunxiao Z, Jian C, Zhu H, Liping G. Diagnostic value of contrast-enhanced ultrasound parametric imaging in breast tumors. *J Breast Cancer* 2013; **16**: 208-213 [PMID: 23843855 DOI: 10.4048/jbc.2013.16.2.208]

18 **van Esser S**, Veldhuis WB, van Hillegersberg R, van Diest PJ, Stapper G, ElOuamari M, Borel Rinkes IH, Mali WP, van den Bosch MA. Accuracy of contrast-enhanced breast ultrasound for pre-operative tumor size assessment in patients diagnosed with invasive ductal carcinoma of the breast. *Cancer Imaging* 2007; **7**: 63-68 [PMID: 17513187 DOI: 10.1102/1470-7330.2007.0012]

19 **Satake H**, Shimamoto K, Sawaki A, Niimi R, Ando Y, Ishiguchi T, Ishigaki T, Yamakawa K, Nagasaka T, Funahashi H. Role of ultrasonography in the detection of intraductal spread of breast cancer: correlation with pathologic findings, mammography and MR imaging. *Eur Radiol* 2000; **10**: 1726-1732 [PMID: 11097398 DOI: 10.1007/s003300000465]

20 **Less JR**, Skalak TC, Sevick EM, Jain RK. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. *Cancer Res* 1991; **51**: 265-273 [PMID: 1988088]

21 **Li X**, Li Y, Zhu Y, Fu L, Liu P. Association between enhancement patterns and parameters of contrast-enhanced ultrasound and microvessel distribution in breast cancer. *Oncol Lett* 2018; **15**: 5643-5649 [PMID: 29556301 DOI: 10.3892/ol.2018.8078]

22 **Choi JS**, Han BK, Ko EY, Ko ES, Shin JH, Kim GR. Additional diagnostic value of shear-wave elastography and color Doppler US for evaluation of breast non-mass lesions detected at B-mode US. *Eur Radiol* 2016; **26**: 3542-3549 [PMID: 26787603 DOI: 10.1007/s00330-015-4201-6]

23 **Lee J**, Lee JH, Baik S, Cho E, Kim DW, Kwon HJ, Kim EK. Non-mass lesions on screening breast ultrasound. *Med Ultrason* 2016; **18**: 446-451 [PMID: 27981276 DOI: 10.11152/mu-871]

24 **Xiao X**, Dong L, Jiang Q, Guan X, Wu H, Luo B. Incorporating Contrast-Enhanced Ultrasound into the BI-RADS Scoring System Improves Accuracy in Breast Tumor Diagnosis: A Preliminary Study in China. *Ultrasound Med Biol* 2016; **42**: 2630-2638 [PMID: 27544439 DOI: 10.1016/j.ultrasmedbio.2016.07.005]

25 **Hartmann LC**, Degnim AC, Santen RJ, Dupont WD, Ghosh K. Atypical hyperplasia of the breast--risk assessment and management options. *N Engl J Med* 2015; **372**: 78-89 [PMID: 25551530 DOI: 10.1056/NEJMsr1407164]

26 **Ngeow J**, Sesock K, Eng C. Clinical Implications for Germline PTEN Spectrum Disorders. *Endocrinol Metab Clin North Am* 2017; **46**: 503-517 [PMID: 28476234 DOI: 10.1016/j.ecl.2017.01.013]

27 **Liu J**, Gao YH, Li DD, Gao YC, Hou LM, Xie T. Comparative study of contrast-enhanced ultrasound qualitative and quantitative analysis for identifying benign and malignant breast tumor lumps. *Asian Pac J Cancer Prev* 2014; **15**: 8149-8153 [PMID: 25338998 DOI: 10.7314/apjcp.2014.15.19.8149]

28 **Liu H**, Jiang YX, Liu JB, Zhu QL, Sun Q, Chang XY. Contrast-enhanced breast ultrasonography: imaging features with histopathologic correlation. *J Ultrasound Med* 2009; **28**: 911-920 [PMID: 19546333 DOI: 10.7863/jum.2009.28.7.911]

**Footnotes**

**Institutional review board statement:** This study was reviewed and approved by the Ethics Committee of the Beijing Shijitan Hospital Affiliated to Capital Medical University.

**Informed consent statement:** All patients were informed of the purpose and risk of the examination and signed informed consent prior to contrast-enhanced ultrasonography and ultrasonic guidance breast biopsy.

**Conflict-of-interest statement:** All authors declare no conflicts-of-interest related to this article.

**Data sharing statement:** No additional data are available.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** November 25, 2019

**First decision:** December 27, 2019

**Article in press:**

**Specialty type:** Medicine, Research and Experimental

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0


Grade D (Fair): 0

Grade E (Poor): 0


**P-Reviewer:** Munjal K, Tsai CA **S-Editor:** Dou Y **L-Editor:** Filipodia **E-Editor:**

**Figure Legends**

**A**




**B**




**Figure 1** **Fifty-three-year-old woman with a non-mass lesion in her left breast.** A: Grayscale ultrasound image revealing a non-ductal non-mass-like lesion pattern without microcalcification. The original Breast Imaging Reporting and Data System (BI-RADS) category is 4a; B: On contrast-enhanced ultrasonography, the lesion exhibited synchronous enhancement without scope expansion. According to our readjusted BI-RADS method, the BI-RADS category of this lesion was reduced to three categories. The final pathology was adenosis.

**A**




**B**




**Figure 2 Forty-five-year-old woman with a non-mass lesion in her right breast.** A: Grayscale ultrasound image revealing a non-ductal non-mass-like lesionpattern without microcalcification. The original Breast Imaging Reporting and Data System (BI-RADS) category is 4a; B: On contrast-enhanced ultrasonography, the lesion exhibited hyper-enhancement without scope expansion. According to our readjusted BI-RADS method, the BI-RADS category of this lesion remained BI-RADS 4a. The final pathology was sclerosing adenosis.


**A**



**B**



**Figure 3 Fifty-two-year-old woman with a non-mass lesion in her right breast.** A: Grayscale ultrasound image revealing a ductal non-mass-like lesion pattern without microcalcification. The original Breast Imaging Reporting and Data System (BI-RADS) category is 4b; B: On contrast-enhanced ultrasonography, the lesion exhibited hyper-enhancement and scope expansion. According to our readjusted BI-RADS method, the BI-RADS category of this lesion remained BI-RADS 4c. The final pathology was intraductal carcinoma *in situ*.



**Figure 4 Receiver-operating characteristic curves for ultrasonography, ultrasonography + contrast-enhanced ultrasound, and contrast-enhanced ultrasound + Breast Imaging Reporting and Data System.** The area under the curve was 0.752 for ultrasonography, 0.877 for ultrasonography + contrast-enhanced ultrasound, and 0.903 for contrast-enhanced ultrasound + Breast Imaging Reporting and Data System. US: Ultrasonography; CEUS: Contrast-enhanced ultrasound; BI-RADS: Breast Imaging Reporting and Data System.

**Table 1 Pathology of 51 non-mass-like lesions**

|  |  |
| --- | --- |
| **Pathology** | **Numbers** |
| A1 group | 25 |
| Adenosis | 17 |
| Intraductal papilloma | 5 |
| Plasma cell mastitis | 2 |
| Vascular smooth muscle hamartoma  A2 group  Sclerosing adenosis  Epithelial columnar cell lesion  Atypical ductal or lobular hyperplasia | 1  3  1  1  1 |
| B group | 23 |
| Intraductal carcinoma *in situ* | 14 |
| Invasive ductal carcinoma  Invasive lobular carcinoma | 7  1 |
| Mucous carcinoma | 1 |

**Table 2 Clinical information and ultrasonography, and color Doppler flow imaging between benign and malignant non-mass-like lesions**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Parameter** |  | **Pathology, *n* (%)** | | **Total** | **χ2** | ***P* value** |
| **Benign** | **Malignant** |
| Age in yr | ﹤45 | 18 (64.29) | 9 (39.13) | 27 (52.94) | 3.207 | 0.073 |
| ≥ 45 | 10 (35.71) | 14 (60.87) | 24 (47.06) |
| Palpability | No | 19 (67.86) | 12 (52.17) | 31 (60.78) | 1.303 | 0.254 |
| Yes | 9 (32.14) | 11 (47.83) | 20 (39.22) |
| Nipple discharge | No | 20 (71.43) | 18 (78.26) | 38 (74.51) | 0.31 | 0.577 |
| Yes | 8 (28.57) | 5 (21.74) | 13 (25.49) |
| Echogenicity | Hypo-echoic | 14 (50.00) | 13 (56.52) | 27 (52.94) | 0.216 | 0.642 |
| Mixed-echoic | 14 (50.00) | 10 (43.48) | 24 (47.06) |
| Ductal changes | No | 17 (60.71) | 12 (52.17) | 29 (56.86) | 0.375 | 0.54 |
| Yes | 11 (39.29) | 11 (47.83) | 22 (43.14) |
| Rear echo attenuation | No | 25 (89.29) | 16 (69.57) | 41 (80.39) | 1.99 | 0.158 |
| Yes | 3 (10.71) | 7 (30.43) | 10 (19.61) |
| Architectural distortion | No | 27 (96.43) | 17 (73.91) | 44 (86.27) | 1.043 | 0.307 |
| Yes | 1 (3.57) | 6 (26.09) | 7 (13.73) |
| Microcalcifications | No | 24 (85.71) | 10 (43.48) | 34 (66.67) | 10.137 | 0.001b |
| Yes | 4 (14.29) | 13 (56.52) | 17 (33.33) |
| Axillary lymph node | Normal | 26 (92.86) | 17 (73.91) | 43 (84.31) | 1.274 | 0.237 |
| Abnormal | 2 (7.14) | 6 (26.09) | 8 (15.69) |
| CDFI | Scarce | 19 (67.86) | 14 (60.87) | 33 (64.71) | 0.27 | 0.603 |
| Abundant | 9 (32.14) | 9 (39.13) | 18 (35.29) |

b*P* < 0.01. CDFI: Color Doppler flow imaging.

**Table 3 Contrast-enhanced ultrasound imaging between benign and malignant non-mass-like lesions**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Parameter** |  | **Pathology, *n* (%)** | | **Total** | **χ2** | ***P* value** |
| **Benign** | **Malignant** |
|  | Later | 5 (17.86) | 0 (0.00) | 5 (9.80) |  |  |
| Enhancement time | Synchronous | 17 (60.71) | 9 (39.13) | 26 (51.98) | 10.270 | 0.006b |
|  | Earlier | 6 (21.43) | 14 (60.87) | 20 (39.22) |  |  |
|  | Hypo-enhanced | 7 (25.00) | 3 (13.04) | 10 (19.61) |  |  |
| Enhanced intensity | Iso-enhanced | 15 (53.57) | 4 (17.39) | 19 (37.25) | 12.140 | 0.002b |
|  | Hyper-enhanced | 6 (21.43) | 16 (69.57) | 22 (43.14) |  |  |
|  | Diffuse enhancement | 20 (71.43) | 18 (78.26) | 38 (74.51) |  |  |
| Enhancement direction | Centripetal | 4 (14.29) | 2 (8.70) | 6 (11.76) | 0.429 | 0.807 |
|  | Centrifugal | 4 (14.29) | 3 (13.04) | 7 (13.73) |  |  |
| Enhancement mode | Homogeneous | 22 (78.57) | 15 (65.22) | 37 (72.55) | 1.131 | 0.288 |
| Heterogeneous | 6 (21.43) | 8 (34.78) | 14 (27.45) |
| Lesion range | without increase | 26 (92.86) | 8 (34.8) | 34 (66.67) | 22.288 | 0.000b |
| increase | 2 (7.14) | 15 (65.2) | 17 (33.33) |
| regression time | Later | 8 (28.57) | 11 (47.83) | 19 (37.25) | 2.921 | 0.232 |
| synchronous | 15 (53.57) | 7 (30.43) | 22 (43.14) |
| Earlier | 5 (17.86) | 5 (21.74) | 10 (19.61) |
| peripheral blood vessels | No | 21 (75) | 11 (47.83) | 32 (62.75) | 3.989 | 0.046a |
| Yes | 7 (25) | 12 (52.17) | 19 (37.25) |

a*P* < 0.05; b*P* < 0.01.

**Table 4 Protocol for readjusting the Breast Imaging Reporting and Data System category with contrast-enhanced ultrasound**

|  |  |  |
| --- | --- | --- |
| **Initial category** | **Number of independent risk factors** | **Modified BI-RADS category** |
| BI-RADS 4a | 0 | Reduce to 3 category |
|  | 1 | Remains unchanged |
|  | 2 | Increase one category |
| BI-RADS 4b | 0 | Reduce to 3 category |
|  | 1 | Remains unchanged |
|  | 2 | Increase one category |
| BI-RADS 4c | 0 | Reduce to 4a category |
|  | 1 or 2 | Increase to 5 category |

BI-RADS: Breast Imaging Reporting and Data System.

**Table 5 Comparison of initial Breast Imaging Reporting and Data System category, and readjusted Breast Imaging Reporting and Data System category with pathology results**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Methods** | **BI-RADS category** | **Total, *n* (%)** | **Pathology, *n* (%)** | |
| **Benign** | **Malignant** |
| US | 4a | 24 (47.06) | 20 (71.43) | 4 (19.61) |
| 4b | 10 (19.61) | 4 (14.29) | 6 (19.61) |
| 4c | 17 (33.33) | 4 (14.29) | 13 (19.61) |
| CEUS + BI-RADS | 3 | 19 (37.25) | 18 (78.26) | 1 (4.35) |
| 4a | 8 (15.691) | 7 (25.00) | 1 (4.35) |
| 4b | 7 (13.73) | 1 (3.57) | 5 (21.74) |
| 4c | 5 (9.80) | 1 (3.57) | 5 (21.74) |
| 5 | 12 (23.53) | 1 (3.57) | 11 (47.83) |

US: Ultrasonography; BI-RADS: Breast Imaging Reporting and Data System; CEUS: Contrast-enhanced ultrasound.

**Table 6 Diagnostic performance of ultrasonography, ultrasonography + contrast-enhanced ultrasound and contrast-enhanced ultrasound + Breast Imaging Reporting and Data System**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Methods** | **AUC** | **Sensitivity** | **Specificity** | **PPV** | **NPV** | **Accuracy** | **Youden’s index** |
| US | 0.752 | 0.826 | 0.741 | 0.704 | 0.833 | 0.765 | 0.536 |
| US + CEUS | 0.877 | 0.870 | 0.929 | 0.909 | 0.879 | 0.902 | 0.797 |
| CEUS + BI-RADS | 0.903 | 0.913 | 0.892 | 0.875 | 0.926 | 0.902 | 0.800 |

US: Ultrasonography; CEUS: Contrast-enhanced ultrasound; BI-RADS: Breast Imaging Reporting and Data System; AUC: Area under the curve; NPV: Negative predictive value; PPV: Positive predictive value.